A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05083169. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Study identification
- NCT ID
- NCT05083169
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 587 participants
Conditions and interventions
Conditions
Interventions
- Daratumumab Drug
- Pomalidomide Drug
- Dexamethasone Drug
- Bortezomib Drug
- Teclistamab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 14, 2021 (Actual)
- Primary completion
- Aug 1, 2025 (Actual)
- Completion
- Sep 15, 2028 (Estimated)
- Last update posted
- Sep 25, 2026
2021 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | — |
| City of Hope | Duarte | California | 91010 | — |
| Stanford University Medical Center | Stanford | California | 94305-5623 | — |
| Yale University | New Haven | Connecticut | 06510 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Henry Ford Health System | Southfield | Michigan | 48075 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425-8900 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 158 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05083169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05083169 live on ClinicalTrials.gov.